TOPICS: Selective Estrogen Receptor Modulators, tamoxifen, antagonist at breast, agonist at bone and uterus, er/pr positive breast cancer, risk of endometrial cancer, raloxifene, antagonist at breast and uterus, agonist at bone, osteoporosis, risk of thromboembolism, hot flashes, clomiphene, antagonist at estrogen receptors in hypothalamus, increase release of lh and fsh from pituitary gland, infertility caused by anovulation, stimulates ovulation, hot flashes, ovarian enlargement, multiple simultaneous pregnancies, visual disturbances
